Don’t risk losing your cloned UK trade marks

ARTICLE SUMMARY

Have you checked to make sure you have a UK representative appointed for your UK cloned trade mark registrations?

authors
No items found.
Related Services
Related Industries

Have you checked to make sure you have a UK representative appointed for your UK cloned trade mark registrations?

The three-year grace period allowed after the UK’s departure from the EU is due to end on 31 December 2023. After this date, non-UK representatives can no longer be appointed for cloned UK registrations and the UK IPO will not accept any instruction from non-UK representatives with regard to these registrations.

Your registration could therefore be at serious risk if you do not have an appointed UK representative following the above deadline, especially if challenged through non-use or invalidation actions.

If you own a UK registration which begins with UK008 or UK009, contact us now to appoint Potter Clarkson LLP as your UK representative FREE OF CHARGE. We offer very competitive renewal fees and have an award winning trade marks team available to assist with any substantive matters involving these registrations.

Please get in touch with your usual Potter Clarkson attorney or contact info@potterclarkson.com.

Related News

Combination therapies: IP considerations for synergistic biologic products

Combination therapies: IP considerations for synergistic biologic products

Perfect storm – four drivers behind the mRNA litigation wave

Perfect storm – four drivers behind the mRNA litigation wave

Patent landscape and freedom-to-operate analysis for RNA-based therapies: identifying IP risks early

Patent landscape and freedom-to-operate analysis for RNA-based therapies: identifying IP risks early

Kodak v FujiFilm: the Court of Appeal confirms UPC’s long-arm jurisdiction

Kodak v FujiFilm: the Court of Appeal confirms UPC’s long-arm jurisdiction

Comparing EPC Article 53(a) and US patent law in gene editing ethics

Comparing EPC Article 53(a) and US patent law in gene editing ethics

EPO Board of Appeal refers claim interpretation and added matter questions

EPO Board of Appeal refers claim interpretation and added matter questions

Creating an effective IP strategy for CAR-T

Creating an effective IP strategy for CAR-T

When is a synbio company a gene therapy company?

When is a synbio company a gene therapy company?

See All News
No items found.